keyword
MENU ▼
Read by QxMD icon Read
search

Natalizumab

keyword
https://www.readbyqxmd.com/read/29343163/magnetic-resonance-imaging-changes-following-natalizumab-discontinuation-in-multiple-sclerosis-patients-with-progressive-multifocal-leukoencephalopathy
#1
Jérôme Hodel, Blanche Bapst, Olivier Outteryck, Sébastien Verclytte, Vincent Deramecourt, Mohamed Amine Benadjaoud, Jean-Pierre Pruvo, Patrick Vermersch, Xavier Leclerc
BACKGROUND: Detecting early progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS) is clinically relevant. OBJECTIVE: Evaluating magnetic resonance imaging (MRI) changes following natalizumab (NTZ) discontinuation and preceding PML-IRIS. METHODS: MRIs (including diffusion-weighted imaging (DWI), T2-weighted fluid-attenuated inversion recovery (T2-FLAIR), post-contrast T1-weighted sequences) were performed every week following PML diagnosis in 11 consecutive NTZ-PML patients...
January 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29336205/prediction-of-natalizumab-anti-drug-antibodies-persistency
#2
Florian Deisenhammer, Marlies Jank, Anna Lauren, Anders Sjödin, Malin Ryner, Anna Fogdell-Hahn, Claudia Sievers, Raija Lindberg, Poul Erik Jensen, Finn Sellebjerg, Louis Christodoulou, Mary Birchler, Marc Pallardy, Michael Auer, Roland Liblau
BACKGROUND: Anti-drug antibodies (ADA) against natalizumab develop early during treatment. ADA persistency is defined by two consecutive positive results as performed by the current qualitative ELISA assay (positive/negative). Very little is known about the magnitude of the natalizumab ADA response and persistency. DESIGN/METHODS: We developed a highly sensitive natalizumab ADA titration assay on the Meso Scale Discovery (MSD) platform and a pharmacokinetic (PK) assay...
January 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29317954/a-multiple-treatment-comparison-of-eleven-disease-modifying-drugs-used-for-multiple-sclerosis
#3
Vida Hamidi, Elisabeth Couto, Tove Ringerike, Marianne Klemp
Background: Several disease-modifying drug therapies are available for the treatment of multiple sclerosis (MS). To ensure the most appropriate MS management, we assessed the effectiveness and cost-effectiveness of the disease-modifying medicines used for MS. Methods: We conducted a systematic review including 11 disease-modifying drugs used for treatment of adult patients diagnosed with relapsing-remitting MS. We performed a network meta-analysis using both direct and indirect evidence...
February 2018: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/29309484/comparative-effectiveness-of-rituximab-and-other-initial-treatment-choices-for-multiple-sclerosis
#4
Mathias Granqvist, Malin Boremalm, Amyar Poorghobad, Anders Svenningsson, Jonatan Salzer, Thomas Frisell, Fredrik Piehl
Importance: Comparative real-world effectiveness studies of initial disease-modifying treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include rituximab are lacking. Objective: To assess the effectiveness and drug discontinuation rates of rituximab among patients with newly diagnosed RRMS compared with injectable DMTs, dimethyl fumarate, fingolimod, or natalizumab. Design, Setting, and Patients: This retrospective cohort study used prospectively collected data to examine specialized care of 2 Swedish county-based community samples of patients with RRMS...
January 8, 2018: JAMA Neurology
https://www.readbyqxmd.com/read/29309202/alemtuzumab-for-the-treatment-of-multiple-sclerosis
#5
Jennifer R Evan, Subutay Bozkurt, Nikita C Thomas, Francesca Bagnato
Introduction Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. Alemtuzumab is approved in more than 50 countries around the world for the treatment of adult patients with relapsing remitting multiple sclerosis (MS). Areas covered In this review, the authors summarize biological, clinical and safety data related to the use of alemtuzumab in patients with MS. The authors then provide their expert opinion on alemtuzumab and the field as of whole before providing their perspectives for the future...
January 8, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29304497/predictors-of-hematological-abnormalities-in-multiple-sclerosis-patients-treated-with-fingolimod-and-dimethyl-fumarate-and-impact-of-treatment-switch-on-lymphocyte-and-leukocyte-count
#6
M Baharnoori, C T Gonzalez, A Chua, C Diaz-Cruz, B C Healy, J Stankiewicz, H L Weiner, T Chitnis
BACKGROUND: There is limited data regarding the predictors of hematological abnormalities in multiple sclerosis (MS) patients treated with dimethyl fumarate (DMF) or fingolimod (FNG), and the impact of treatment switch on lymphocyte and leukocyte count METHODS: We identified 405 patients on DMF and 300 patients on FNG (treatment duration: at least 12 month) within a large prospective study of MS patients conducted at the Partners MS Center, Brigham and Women's Hospital (CLIMB study) between Jan 2011 to Feb 2016...
December 14, 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29301440/advancing-the-understanding-of-progression-in-multiple-sclerosis-an-interview-with-shibeshih-belachew
#7
Shibeshih Belachew
Shibeshih Belachew speaks to Laura Dormer, Commissioning Editor: Dr Shibeshih Belachew, MD, PhD, is a Senior Medical Director for Multiple Sclerosis (MS) Disease Area in Global Product Development Medical Affairs at Roche (Basel, Switzerland). Prior to joining Roche in January 2016, he was Director of MS Franchise and Head of Medical Director's office for Biogen Region Europe and Canada. Previously at Biogen he also served as a Director in Global Neurology for the natalizumab program in Cambridge (MA, USA)...
January 5, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29205701/antibody-response-to-seasonal-influenza-vaccination-in-multiple-sclerosis-patients-receiving-immunomodulatory-therapy
#8
Henning K Olberg, Geir Egil Eide, Rebecca J Cox, Åsne Jul-Larsen, Sarah Larteley Lartey, Christian A Vedeler, Kjell-Morten Myhr
BACKGROUND: We have previously shown that multiple sclerosis patients receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization. OBJECTIVES: To further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls. METHODS: Ninety patients receiving fingolimod, glatiramer acetate, interferon beta-1a/1b, natalizumab or no therapy were compared to 62 healthy controls...
December 4, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29198860/comparative-of-transcranial-magnetic-stimulation-and-other-treatments-in-experimental-autoimmune-encephalomyelitis
#9
Francisco J Medina-Fernandez, Begoña M Escribano, Evelio Luque, Javier Caballero-Villarraso, Jose L Gomez-Chaparro, Montserrat Feijoo, Fe I Garcia-Maceira, Alvaro Pacual-Leone, René Drucker-Colin, Isaac Tunez
The effects of transcranial magnetic stimulation (TMS), natalizumab (nata), dimethyl fumarate (DMF) and dexamethasone (DEX) on clinical score and oxidative stress produced by a single dose of myelin oligodendrocyte glycoprotein (MOG) in tail of Dark Agouti rats was studied. TMS (60Hz and 0.7 mT), nata (5mg/kg), DMF (15mg/kg) and DEX (300μg/kg) was applied for 21 after the administration of MOG (150μg). We estimated clinical score, as well as lipid peroxides, carbonylated proteins and reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio content in brain, spinal cord and blood...
December 1, 2017: Brain Research Bulletin
https://www.readbyqxmd.com/read/29185135/disease-modifying-treatments-modulate-myeloid-cells-in-multiple-sclerosis-patients
#10
Gloria Dalla Costa, Annamaria Finardi, Livia Garzetti, Tiziana Carandini, Giancarlo Comi, Vittorio Martinelli, Roberto Furlan
The role of myeloid cells in the pathogenesis of MS is determined by the polarization they acquire after activation, and mediated by release of extracellular vesicles (MVs). We assessed the effects of treatments for MS on activation and polarization of myeloid cells. MVs levels and markers of polarization of myeloid cells have been assessed at baseline and up to 6 months after the start of a MS treatment. Patients had higher levels of MVs than controls, and these increased significantly over 6 months under natalizumab...
November 28, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/29161897/status-epilepticus-and-multiple-sclerosis-a-case-presentation-and-literature-review
#11
Murat Mert Atmaca, Candan Gurses
PURPOSE: To search the literature for the frequency, pathogenesis, prognosis, and treatment of seizures and status epilepticus (SE) in patients with multiple sclerosis (MS). METHODS: We report 2 patients with MS who presented with SE and review the literature. RESULTS: Seizures and SE episodes worsened during MS relapses in the first patient. SE episodes and MS relapses significantly decreased after initiation of natalizumab treatment but she still had seizures and was taking 4 antiepileptic drugs (AEDs)...
January 1, 2017: Clinical EEG and Neuroscience: Official Journal of the EEG and Clinical Neuroscience Society (ENCS)
https://www.readbyqxmd.com/read/29159801/real-life-clinical-use-of-natalizumab-and-fingolimod-in-austria
#12
M Guger, C Enzinger, F Leutmezer, J Kraus, S Kalcher, E Kvas, T Berger
OBJECTIVES: To compare the efficacy of natalizumab or fingolimod in a nationwide observational cohort using prospectively collected data. MATERIALS AND METHODS: We included all patients starting treatment with natalizumab or fingolimod documented in the Austrian MS Treatment Registry (AMSTR) from 2011 and staying on therapy for at least 24 months. We used propensity scores for several matching methods and as a covariate in multivariate models to correct for the bias of this non-randomized registry study...
November 20, 2017: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/29149804/systematic-literature-review-and-network-meta-analysis-of-cladribine-tablets-versus-alternative-disease-modifying-treatments-for-relapsing-remitting-multiple-sclerosis
#13
M K Siddiqui, I S Khurana, S Budhia, R Hettle, G Harty, S L Wong
OBJECTIVE: To assess the comparative efficacy and safety of cladribine tablets versus alternative disease modifying treatments (DMTs) in patients with active relapsing-remitting multiple sclerosis (RRMS), and in a subgroup with high disease activity (HRA+DAT), using systematic literature review (SLR) and network meta-analysis (NMA). METHODS: MEDLINE, Embase, MEDLINE In-Process and CENTRAL databases were systematically searched to identify English-language publications of relevant studies of approved DMTs for RRMS...
November 17, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29143589/biomarkers-in-the-evolution-of-multiple-sclerosis
#14
Thomas Berger
Nonimaging biomarkers can be applied in differential diagnosis, evaluation of disease progression and therapy monitoring of multiple sclerosis (MS). Presence of oligoclonal IgG bands in cerebrospinal fluid is a diagnostic element and a negative predictor of MS evolution. AQP4 antibodies are pathogenic and diagnostic for neuromyelitis optica spectrum disorder. Antibodies to myelin oligodendrocyte glycoprotein develop in about 50% of predominantly pediatric patients with acute disseminated encephalomyelitis, but their possible role in pathogenesis is unknown...
November 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29142146/inflammatory-natalizumab-associated-pml-baseline-characteristics-lesion-evolution-and-relation-with-pml-iris
#15
Mike P Wattjes, Martijn T Wijburg, Jeroen van Eijk, Stephan Frequin, Bernard M J Uitdehaag, Frederik Barkhof, Clemens Warnke, Joep Killestein
BACKGROUND AND OBJECTIVE: Natalizumab-associated progressive multifocal leukoencephalopathy (NTZ-PML) patients may show imaging signs suggestive of inflammation at diagnosis ('inflammatory PML'), reminiscent of PML-immune reconstitution inflammatory syndrome (PML-IRIS). We investigated the imaging characteristics of inflammatory NTZ-PML lesions and PML-IRIS to determine differentiating and overlapping features. METHODS: We scored the presence, localisation and pattern of imaging characteristics of inflammation on brain MRI scans of inflammatory NTZ-PML patients...
November 15, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29141809/treatment-satisfaction-across-injectable-infusion-and-oral-disease-modifying-therapies-for-multiple-sclerosis
#16
Tessa Eagle, Fiona Stuart, Alicia S Chua, Allison LaRussa, Kaitlynne Leclaire, Sandra L Cook, Tanuja Chitnis, Howard L Weiner, Bonnie I Glanz, Brian C Healy
BACKGROUND: The recent approval of oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) has provided patients with a new route of therapy administration. Little research has compared patients' experiences with and perceptions of injectable, infusion and oral MS therapies. METHODS: Three hundred fifty-seven treated MS patients enrolled in the CLIMB study completed the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM provides information regarding perceived effectiveness, side effects, convenience and overall satisfaction...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29138683/the-evaluation-of-oxidative-stress-parameters-in-serum-patients-with-relapsing-remitting-multiple-sclerosis-treated-with-ii-line-immunomodulatory-therapy
#17
Bożena Adamczyk, Sławomir Wawrzyniak, Sławomir Kasperczyk, Monika Adamczyk-Sowa
Objectives: The assessment of oxidative stress (OS) in serum relapsing-remitting multiple sclerosis patients treated with II-line immunomodulatory therapy (fingolimod, natalizumab) compared to newly diagnosed patients (de novo group) treated with interferon (IFN) beta and controls. The relationship between OS parameters and gender, age, disease duration, Expanded Disability Status Scale, annualized relapse rate, MRI lesions in patients treated with II-line. Materials and Methods: One hundred and twenty-one patients with RRMS were enrolled in the study...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/29119538/safety-and-effectiveness-of-natalizumab-first-report-of-interim-results-of-post-marketing-surveillance-in-japan
#18
Takahiko Saida, Kazumasa Yokoyama, Ryusuke Sato, Haruki Makioka, Yukihiko Iizuka, Masakazu Hase, Yan Ling, Shinichi Torii
INTRODUCTION: Natalizumab, a humanized anti-α4 integrin monoclonal antibody, received marketing approval in Japan in 2014 for the treatment of multiple sclerosis (MS). Because the previous large-scale clinical trials of natalizumab were mainly conducted in Europe and North American countries, and data in patients with MS from Japan were limited, we conducted an all-case post-marketing surveillance of natalizumab-treated MS patients from Japan to investigate the safety and effectiveness of natalizumab in a real-world clinical setting in Japan...
November 8, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/29116601/abnormal-cervical-lymph-nodes-in-multiple-sclerosis-a-preliminary-ultrasound-study
#19
Francesca Di Giuliano, Maria Albanese, Eliseo Picchi, Francesco Mori, Fabio Buttari, Girolama Alessandra Marfia, Francesco Garaci, Nicola Biagio Mercuri, Roberto Floris, Diego Centonze, Simone Marziali
BACKGROUND: Cervical lymph nodes are the first drainage stations of the brain and therefore play a key role in neuroinflammatory disorders such as multiple sclerosis. OBJECTIVE: The aim of this study was to evaluate, by using ultrasound imaging, cervical lymph nodes in patients with multiple sclerosis and to ascertain if such patients have any clinical features to attest their role. METHODS: We enrolled 43 patients affected by relapsing-remitting multiple sclerosis (22 drug free and 21 under treatment with natalizumab or fingolimod), who underwent ultrasound examination...
November 7, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/29111011/improvement-of-quality-of-life-and-its-relationship-with-neuropsychiatric-outcomes-in-patients-with-multiple-sclerosis-starting-treatment-with-natalizumab-a-3-year-follow-up-multicentric-study
#20
Vincent Planche, Xavier Moisset, Remy Morello, Emilie Dumont, Marion Gibelin, Julie Charré-Morin, Aurore Saubusse, Audrey Mondou, Françoise Reuter, Gilles Defer, Jean Pelletier, Bruno Brochet, Pierre Clavelou
BACKGROUND: Health-related quality of life (HRQoL) is impaired in multiple sclerosis (MS) but can be improved by disease-modifying therapies such as natalizumab. However, the predictive factors and neuropsychiatric correlates of HRQoL improvement are unknown. METHODS: In this study, 48 patients with relapsing-remitting MS were included in a 3-year open-label, single group, multicenter, clinical trial (NCT01392872). HRQoL was measured by the disease-specific MusiQoL questionnaire, together with physical disability, cognition, fatigue, anxiety and depression scores at baseline, 6months, 12months, 18months and 36months after starting natalizumab therapy...
November 15, 2017: Journal of the Neurological Sciences
keyword
keyword
27292
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"